Targeting MTAP increases PARP inhibitor susceptibility in triple-negative breast cancer through a feed-forward loop
Journal of Clinical Investigation · 01.07.2025 · 135 (13)
DOI: 10.1172/jci188120 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Investigation, online erschienen am 01.07.2025. Verfasst von Xiangyu Zeng und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastrointestinal Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. Hauptthemen laut MEDLINE: Triple Negative Breast Neoplasms, Poly(ADP-ribose) Polymerase Inhibitors, Neoplasm Proteins. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 64 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, the National Natural Science Foundation of China, the Provincial Natural Science Foundation of Hunan.
Abstract (Originalsprache)
Triple-negative breast cancer (TNBC) represents the most malignant subtype of breast cancer. The clinical application of PARP inhibitors (PARPi) is limited by the low frequency of BRCA1/2 mutations in TNBC. Here, we identified that MTAP deletion sensitized genotoxic agents in our clinical cohort of metastatic TNBC. Further study demonstrated that MTAP deficiency or inhibition rendered TNBC susceptibility to chemotherapeutic agents, particularly PARPi. Mechanistically, targeting MTAP that synergized with PARPi by disrupting the METTL16-MAT2A axis involved in methionine metabolism and depleting in vivo s-adenosylmethionine (SAM) levels. Exhausted SAM in turn impaired PARPi-induced DNA damage repair through attenuation of MRE11 recruitment and end resection by diminishing MRE11 methylation. Notably, brain metastatic TNBC markedly benefited from a lower dose of PARPi and MTAP deficiency/inhibition synergy due to the inherently limited methionine environment in the brain. Collectively, our findings revealed a feed-forward loop between methionine metabolism and DNA repair through SAM, highlighting a therapeutic strategy of PARPi combined with MTAP deficiency/inhibition for TNBC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gastrointestinal Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
- College of Biology, Hunan University, Changsha, China.
- Department of Oncology, Mayo Clinic, Rochester, Minnesota, USA.
- Department of Radiation Oncology, Hubei Cancer Hospital, Tongji Medical College, and.
- Department of Breast and Thyroid Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
- Department of Breast Surgery, Guizhou Provincial People's Hospital, Guiyang, China.
Förderung
- NCI NIH HHS
- the National Natural Science Foundation of China
- the Provincial Natural Science Foundation of Hunan
- the Special Research Fund of the Wuhan Knowledge Innovation Program
Zitieren
APA
Zeng, X., Zhao, F., Tu, X., Zhang, Y., Yang, W., Hou, J., Jiang, Q., Zhu, S., Wu, Z., Hao, Y., Zhang, L., Weinshilboum, R. M., Tao, K., Wang, L., & Lou, Z. (2025). Targeting MTAP increases PARP inhibitor susceptibility in triple-negative breast cancer through a feed-forward loop. Journal of Clinical Investigation, 135(13). https://doi.org/10.1172/jci188120
Vancouver
Zeng X, Zhao F, Tu X, Zhang Y, Yang W, Hou J, et al. Targeting MTAP increases PARP inhibitor susceptibility in triple-negative breast cancer through a feed-forward loop. Journal of Clinical Investigation. 2025;135(13). doi:10.1172/jci188120
BibTeX
@article{Zeng2025,
author = {Zeng, Xiangyu and Zhao, Fei and Tu, Xinyi and Zhang, Yong and Yang, Wen and Hou, Jing and Jiang, Qi and Zhu, Shouhai and Wu, Zheming and Hao, Yalan and Zhang, Lingxin and Weinshilboum, Richard M and Tao, Kaixiong and Wang, Liewei and Lou, Zhenkun},
title = {Targeting MTAP increases PARP inhibitor susceptibility in triple-negative breast cancer through a feed-forward loop},
journal = {Journal of Clinical Investigation},
year = {2025},
volume = {135},
number = {13},
doi = {10.1172/jci188120}
}
EUVIMED